Mereo signs alvelestat U.S. option and license deal with Sentynl Therapeutics
Mereo BioPharma entered into an Option and License Agreement with Sentynl Therapeutics on August 11, 2026, covering U.S. commercial rights and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo keeps rest-of-world rights and will lead the global Phase 3 study, with the companies refining the study design during the option period. For shareholders, the deal provides for a non-refundable option fee and, on option exercise, $40 million in upfront and R&D payments plus up to $435 million in potential milestones and double-digit tiered royalties on U.S. sales, though these payments depend on Sentynl exercising the option.
Key points
- Sentynl gets the option to license U.S. commercialization of alvelestat; Mereo keeps rest-of-world rights and leads global Phase 3 development
- On option exercise, Mereo is eligible to receive $40 million in upfront and R&D payments
- Mereo is also eligible for up to $435 million in potential milestones and double-digit tiered royalties on U.S. sales
- The agreement is dated August 11, 2026; the full agreement is expected to be filed with the 10-Q for the quarter ending September 30, 2026
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.